Traded Jul 1, 2026 · Filed Jul 2, 2026
The boss of Gilead Sciences sold $394K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$393,933
Shares × reported transaction price
55 days after results of May 7, 2026, 34 days before results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $125.97 on Jul 1, 2026, 16% above its 52-week low and 19% below its high, after a 3% drop over the previous 30 trading days
52-week range $108.22 (Jul 18, 2025) to $155.80 (Feb 11, 2026), 37% of the way up, from 251 adjusted closes. 30 trading days earlier: $129.67 on May 18, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Trodelvy on Jun 24, 2026, 7 days before this trade.
New use approved (efficacy supplement). Active ingredient: Sacituzumab Govitecan-Hziy. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.4% | -0.3% | +1.7% |
| 30 days | +1.7% | +2.5% | -0.8% |
Past results only. Not a forecast.
3 different filers disclosed GILD within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.
CFO sold ~$390K of Gilead Sciences
Scheduled in advanceOfficer sold ~$390K of Gilead Sciences
Scheduled in advance